Tag - Kyle Mikson

Markets

Canaccord cuts T2 Biosystems to hold on Q3 results and guidance

Canaccord Genuity Capital Markets downgraded T2 Biosystems (NASDAQ:TTOO) to “hold” from “buy” and slashed its price target to $2.50 from $12.50, adjusted for the recent 1-for-50 reverse stock split after the company...

October 14, 2022

Markets

AGP ups T2 BioSystems to buy; Canaccord cuts PT to $1.50 from $3

Following the fourth quarter report for T2 BioSystems (NASDAQ:TTOO), Alliance Global Partners upgraded T2 to “buy” from “neutral” and raised its price target to 70 cents from 55 cents, while Canaccord Genuity reduced...

February 18, 2022

Markets

Analysts start Lucid Diagnostics at buy: PTs $14, $18

Analysts for BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics (NASDAQ:LUCD) with “buy” ratings and price targets of $14 and $18, respectively. The stock closed at $9.52 on Oct. 5. Lucid recently...

November 8, 2021

Markets

Cantor starts PAVmed at OW; PT $8

Cantor Fitzgerald initiated coverage of PAVmed (NASDAQ:PAVM) with an “overweight” rating and price target of $8. The stock closed at $3.93 on March 29. The company employs a unique business model that emphasizes capital...

March 29, 2021

Tag - Kyle Mikson

Canaccord cuts T2 Biosystems to hold on Q3 results and guidance

AGP ups T2 BioSystems to buy; Canaccord cuts PT to $1.50 from $3

Analysts start Lucid Diagnostics at buy: PTs $14, $18

Cantor starts PAVmed at OW; PT $8

General

More